Marie-Hélène Delfau-Larue

10PUBLICATIONS
54CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 04, 2025
Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.

Olivier Tournilhac, Kamal Bouabdallah, Solène Lecolant

|Jun 11, 2025
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.

Alexis Claudel, Anne-Ségolène Cottereau, Emmanuel Bachy

|Apr 26, 2024
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.

Clémentine Sarkozy, Mary Callanan, Catherine Thieblemont

|Feb 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.

Vincent Camus, Catherine Thieblemont, Philippe Gaulard

|Nov 22, 2023
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.

Eva Hoster, Marie-Hélène Delfau-Larue, Elizabeth Macintyre

|Apr 10, 2023
Baseline circulating tumour DNA and total metabolic tumour volume as early outcome predictors in aggressive large B-cell lymphoma. A real-world 112-patient cohort.

Enora Le Goff, Paul Blanc-Durand, Louise Roulin

Pageof 2

Frequent Collaborators

5 joint publications

Franck Morschhauser

4 joint publications

Emmanuel Bachy

4 joint publications

Vincent Camus

3 joint publications

Philippe Gaulard